Orthofix International N.V. (Orthofix) — FY 2014 Form 10-K
Reporting period: Year ended December 31, 2014; filed April 29, 2015. This is an annual report, not a standalone Q4 filing. The registrant identifies itself as Orthofix International N.V.; the filing reports consolidated results for its BioStim, Biologics, Extremity Fixation and Spine Fixation businesses.
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Net sales | $402.3 million | $397.6 million |
| Gross profit / margin | $303.4 million / 75.4% | $290.7 million / 73.1% |
| Operating income (loss) | $17.1 million | $(11.2) million |
| Net income (loss) | $(8.5) million; $(0.46) per share | $(28.8) million; $(1.54) per share |
| Cash from operations | $51.0 million | $67.0 million |
- Sales increased 1.2% year over year. Gross margin improved mainly because inventory reserve charges were lower than in 2013.
- FY 2014 continuing-operations loss was $3.7 million. Income-tax expense was $16.2 million despite $12.5 million of pretax income, producing a reported effective tax rate of 130.1%. Discontinued operations added a $4.8 million net loss, primarily related to legacy Breg matters.
- Q4 2014 sales were $100.3 million versus $105.9 million in Q4 2013. Q4 operating income was $4.0 million and net loss was $5.8 million, compared with a $10.1 million operating loss and $10.4 million net loss in Q4 2013.
- Cash and cash equivalents were $36.8 million and restricted cash was $34.4 million at year-end, for $71.2 million combined. Current assets were $256.4 million and current liabilities $66.4 million.
- No borrowings remained under the main credit facilities at year-end; the company repaid $20.0 million of debt in 2014. The available revolving facility was reduced to $100 million in January 2015 and was due to expire August 30, 2015. Italian borrowing capacity was also available, with no borrowings outstanding.
- Capital expenditures were $18.5 million. Operating cash flow declined $16.1 million year over year; management cited lower non-cash adjustments, partly offset by working-capital performance. Days sales outstanding improved to 56 from 62, and inventory turns rose to 1.7 from 1.5.
Material changes versus prior periods
- BioStim sales rose 6.6% to $154.7 million; Biologics rose 4.0% to $55.9 million; Extremity Fixation rose 6.1% to $109.7 million. Spine Fixation fell 14.0% to $82.0 million, reflecting sales-force reorganization and lost sales momentum.
- Sales and marketing expense fell 5.1% to $166.5 million. General and administrative expense increased 18.4% to $76.8 million, including increased investment in audit, control and process improvements and $3.8 million of Bluecore costs.
- R&D expense decreased to $25.0 million from $26.8 million. Accounting-review and restatement costs were $15.6 million in 2014 versus $12.9 million in 2013. The $19.2 million goodwill impairment recorded in 2013 did not recur.
- Sales remained well below 2012’s $440.2 million, when BioStim revenue was higher. The company’s 2013 distributor revenue recognition transition and other restatement-related adjustments affect comparisons across periods.
Outlook, risks and unusual items
- 2015 outlook: Net sales of $385 million to $390 million and adjusted EBITDA of $55 million to $58 million. Management described the sales range as a 0.7% decline to 0.6% growth on a constant-currency basis, and a 4.3% to 3.1% decline as reported.
- Management planned $20 million to $25 million of 2015 capital expenditures. Bluecore, a multi-year systems and process initiative expected to run through mid-2017, has an estimated total budget of about $30 million; approximately $19 million was budgeted for 2015.
- Restatements and controls: The company completed a further restatement in March 2015 after an earlier restatement in 2014. Management and Ernst & Young concluded that internal control over financial reporting was ineffective at December 31, 2014, citing material weaknesses in distributor revenue recognition, receivables reserves, inventory reserves, foreign-subsidiary oversight and manual journal entries. The financial-statement audit opinion was unqualified; the separate internal-control opinion was adverse.
- Regulatory and litigation exposure: The SEC is conducting a formal investigation related to accounting and controls, and a securities class action remained pending; the court dismissed claims against one former executive but allowed claims against the company and others to proceed. The company could not reasonably estimate possible losses for these matters.
- An investigation of alleged improper payments involving the Brazil subsidiary was ongoing and had been self-reported to the DOJ and SEC; loss exposure was not estimable. The company also remained subject to a five-year HHS-OIG Corporate Integrity Agreement and a DOJ deferred prosecution agreement, with potential consequences for noncompliance.
- Legacy Breg indemnification claims continued. The filing reports $3.8 million of 2014 losses from infusion-pump litigation and a $5.7 million accrual for specified cold-therapy liabilities; additional exposure was uncertain.
- Timely SEC filings and Nasdaq listing remained important risks following late filings. Listing relief was conditional on future reporting compliance. Other key risks include reimbursement changes, product regulation and acceptance, dependence on tissue supplier MTF, foreign exchange, and refinancing or replacing the revolving facility before its August 2015 expiration.
- Subsequent events included a $4.8 million sale of the Tempus cervical plate product line and an 18-month option to acquire eNeura. The option involved a $15 million, 8% convertible note to Orthofix and a potential $65 million acquisition payment, subject to adjustments and possible milestone payments.
Most important facts for investors to verify
- Review the restated statements and notes, especially distributor revenue recognition, inventory and receivables reserves, and any further developments in the SEC investigation or remediation plan.
- Track whether the company remediates all five material weaknesses and files subsequent periodic reports on time, preserving Nasdaq listing and access to capital markets.
- Assess the August 2015 credit-facility expiration, available borrowing capacity, cash restrictions and the company’s ability to replace or extend the facility on acceptable terms.
- Monitor 2015 performance against the sales and adjusted EBITDA outlook, particularly the continuing decline or recovery in Spine Fixation and the progress of other segments.
- Confirm the eventual financial and operational impact of Brazil-related allegations, pending securities litigation, Breg indemnification claims and compliance obligations; several exposures were not reasonably estimable in the filing.